Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gensight Biologics SA

http://www.gensight-biologics.com

Latest From Gensight Biologics SA

Novartis Doubles Up In Optogenetics With Arctos Buy

The Basel-based major has swooped to buy fellow Swiss group Arctos in the belief that optogenetics is a promising therapeutic approach that might restore sight to patients who are legally blind.

M & A Gene Therapy

REFLECT Study Confirms Efficacy Of GenSight's Gene Therapy Lumevoq

French biotech GenSight Biologics reports top-line results from the Phase III REFLECT study, backing the efficacy of its lead gene therapy in a devastating eye disease, and prepares plans to commercialize the product.

Gene Therapy Ophthalmic

GenSight CEO Sees Bright Future After Therapy Gave Blind Man Partial Sight

French biotech GenSight will prioritize its optogenetic GS030 treatment after the combination showed breakthrough results in a form of blindness, its CEO tells Scrip.

Clinical Trials Gene Therapy
See All

Company Information

UsernamePublicRestriction

Register